Nanologica AB (publ) (NICA.ST)
SEK 1.71
(-0.58%)
SEK 1.71
(-0.58%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -76 Thousand SEK | -1580.87% |
| 2022 | 3.23 Million SEK | -34.25% |
| 2021 | 4.92 Million SEK | -67.18% |
| 2020 | 14.99 Million SEK | 73.03% |
| 2019 | 8.66 Million SEK | 467.73% |
| 2018 | 1.52 Million SEK | -76.4% |
| 2017 | 6.46 Million SEK | 224.63% |
| 2016 | 1.99 Million SEK | -68.95% |
| 2015 | 6.41 Million SEK | 15.92% |
| 2014 | 5.53 Million SEK | 114.89% |
| 2013 | 2.57 Million SEK | 32.56% |
| 2012 | 1.94 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -10.19 Million SEK | 60.53% |
| 2024 Q2 | -10.17 Million SEK | 107.19% |
| 2023 Q1 | 1.42 Million SEK | -0.7% |
| 2023 Q3 | -372 Thousand SEK | -157.67% |
| 2023 Q2 | 645 Thousand SEK | -54.67% |
| 2023 FY | -47.9 Million SEK | -1580.87% |
| 2023 Q4 | -25.82 Million SEK | -6841.67% |
| 2022 Q3 | 1.35 Million SEK | 19.43% |
| 2022 Q2 | 1.13 Million SEK | 266.23% |
| 2022 FY | 3.23 Million SEK | -34.25% |
| 2022 Q1 | -681 Thousand SEK | 68.3% |
| 2022 Q4 | 1.43 Million SEK | 5.99% |
| 2021 Q1 | 3.85 Million SEK | -8.95% |
| 2021 FY | 4.92 Million SEK | -67.18% |
| 2021 Q2 | 3.02 Million SEK | -21.47% |
| 2021 Q4 | -2.14 Million SEK | -1280.22% |
| 2021 Q3 | 182 Thousand SEK | -93.99% |
| 2020 Q1 | 2.67 Million SEK | 43.01% |
| 2020 FY | 14.99 Million SEK | 73.03% |
| 2020 Q4 | 4.23 Million SEK | 64.53% |
| 2020 Q2 | 5.5 Million SEK | 105.79% |
| 2020 Q3 | 2.57 Million SEK | -53.26% |
| 2019 FY | 8.66 Million SEK | 467.73% |
| 2019 Q3 | 1.4 Million SEK | -49.89% |
| 2019 Q2 | 2.81 Million SEK | 9.72% |
| 2019 Q1 | 2.56 Million SEK | 12515.14% |
| 2019 Q4 | 1.87 Million SEK | 32.9% |
| 2018 Q1 | 514 Thousand SEK | -91.62% |
| 2018 Q2 | 548 Thousand SEK | 6.61% |
| 2018 Q3 | 443 Thousand SEK | -19.16% |
| 2018 Q4 | 20.3 Thousand SEK | -95.42% |
| 2018 FY | 1.52 Million SEK | -76.4% |
| 2017 Q2 | 589 Thousand SEK | 280.0% |
| 2017 FY | 6.46 Million SEK | 224.63% |
| 2017 Q4 | 6.13 Million SEK | 4377.0% |
| 2017 Q3 | 137 Thousand SEK | -76.74% |
| 2017 Q1 | 155 Thousand SEK | -93.74% |
| 2016 Q1 | 623 Thousand SEK | -49.7% |
| 2016 FY | 1.99 Million SEK | -68.95% |
| 2016 Q4 | 2.47 Million SEK | 2391.89% |
| 2016 Q3 | -108 Thousand SEK | 59.25% |
| 2016 Q2 | -265 Thousand SEK | -142.54% |
| 2015 Q4 | 1.23 Million SEK | -33.16% |
| 2015 Q1 | 1.94 Million SEK | 78.84% |
| 2015 Q2 | 1.51 Million SEK | -22.33% |
| 2015 FY | 6.41 Million SEK | 15.92% |
| 2015 Q3 | 1.85 Million SEK | 22.72% |
| 2014 Q4 | 1.08 Million SEK | 0.0% |
| 2014 Q2 | 1.9 Million SEK | 0.0% |
| 2014 Q1 | 1.9 Million SEK | 0.0% |
| 2014 FY | 5.53 Million SEK | 114.89% |
| 2014 Q3 | 1.08 Million SEK | -42.93% |
| 2013 FY | 2.57 Million SEK | 32.56% |
| 2012 FY | 1.94 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 99.953% |
| Ziccum AB (publ) | -23.28 Million SEK | 99.674% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 100.022% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 100.182% |
| Mendus AB (publ) | 28.48 Million SEK | 100.267% |
| Genovis AB (publ.) | 54 Million SEK | 100.141% |
| Intervacc AB (publ) | -13.79 Million SEK | 99.449% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 103.501% |
| Active Biotech AB (publ) | -1.67 Million SEK | 95.463% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 100.763% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 100.283% |
| Aptahem AB (publ) | 2.63 Million SEK | 102.889% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 97.778% |
| Kancera AB (publ) | -1.96 Million SEK | 96.132% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | 198.701% |
| Fluicell AB (publ) | 1.73 Million SEK | 104.373% |
| Saniona AB (publ) | 11.78 Million SEK | 100.645% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 98.515% |
| Biovica International AB (publ) | 6.87 Million SEK | 101.105% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 99.674% |
| AcouSort AB (publ) | 8.38 Million SEK | 100.906% |
| Xintela AB (publ) | 78 Thousand SEK | 197.436% |
| Abliva AB (publ) | -35.66 Million SEK | 99.787% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 99.948% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 102.708% |
| OncoZenge AB (publ) | 3000.00 SEK | 2633.333% |
| Amniotics AB (publ) | -1.93 Million SEK | 96.062% |
| 2cureX AB (publ) | -37.48 Million SEK | 99.797% |
| CombiGene AB (publ) | -21.29 Million SEK | 99.643% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | 82.033% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 100.007% |
| Camurus AB (publ) | 1.58 Billion SEK | 100.005% |
| Corline Biomedical AB | 28.38 Million SEK | 100.268% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 99.938% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 99.779% |
| I-Tech AB | 27.56 Million SEK | 100.276% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 100.107% |
| Cyxone AB (publ) | 2.61 Million SEK | 102.911% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 102.233% |
| Biosergen AB | -456 Thousand SEK | 83.333% |
| Cantargia AB (publ) | -3.45 Million SEK | 97.798% |
| NextCell Pharma AB | -43.74 Million SEK | 99.826% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 99.173% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 100.677% |
| SynAct Pharma AB | -778 Thousand SEK | 90.231% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | 60.622% |
| Stayble Therapeutics AB (publ) | - SEK | Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 99.412% |
| Lipum AB (publ) | 53 Thousand SEK | 243.396% |
| BioInvent International AB (publ) | 71.46 Million SEK | 100.106% |
| Alzinova AB (publ) | 19.87 Million SEK | 100.382% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 100.209% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 105.195% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | -406.667% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | 104.584% |
| Simris Alg AB (publ) | 2 Million SEK | 103.787% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 97.877% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 100.215% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | 92.755% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 102.426% |